Endocrine Oncology
Read Time: 5 mins

Tumour-induced Osteomalacia Secondary to a Sarcoma

Copy Link
Published Online: Aug 29th 2016 European Endocrinology, 2016;12(2):104–6 DOI:
Authors: Karla Victoria Rodriguez-Velver, Maria Azucena Zapata-Rivera, Juan Montes-Villarreal, Fernando Javier Lavalle-González, José Gerardo Gonzalez-Gonzalez, Jesus Zacarias Villarreal-Perez, René Rodríguez-Gutiérrez
Quick Links:
Article Information

Tumour-induced osteomalacia (TIO), is a rare paraneoplasatic syndrome found in >95% of benign tumours that secrete fibroblast growth factor 23 - a phosphaturic circulating hormone. A rare case of a TIO secondary to a sarcoma, in a 21-year old man with history of bone fractures and distinctive physical and biochemical characteristics is presented and discussed.


Tumour-induced osteomalacia, hypophosphatemia, fibroblast growth factor 23


Oncogenic osteomalcia, also known as tumour-induced osteomalacia (TIO), is a rare paraneoplasatic syndrome with around 350 reported cases.1 TIO initial symptoms are nonspecific and include fatigue, bone pain, muscle weakness, weight, and height loss, and later bone deformity and fractures. It is characterised by hypophosphatemia, hyperphosphaturia, elevated alkaline phosphatase, and low serum 1-25(OH) vitamin D. Pathophysiologically, TIO is caused by tumours that secrete fibroblast growth factor 23 (FGF-23), a phosphaturic circulating hormone.

TIO tumours are usually benign (in >95% of cases), however, they are a diagnostic challenge owing to their small size (usually less than 1 cm), which makes them difficult to localise. The differential diagnoses are genetic causes such as X-linked hypophosphatemic rickets, autosomal dominant and recessive hypophosphatemia, Dent’s disease, idiopathic hypercalciuria, and hereditary hypophosphatemic rickets with hypercaliuria.2 Ten cases of TIO in the literature have been reported to be secondary to sarcomas, however, all of them were reported before it was known that the secreted molecule by these tumours was FGF-23, hence the diagnosis remained ‘uncertain’. Herein, we report the case of a 21-year-old male with a TIO associated with spindle cell sarcoma.

Case report
A 21-year-old man presented for evaluation of a pathological femur fracture. The patient had been otherwise healthy until age 18, when he noted onset of lower back pain after soccer practice, which was exacerbated by exercise and improved when being resting. This pain was progressive and he started noticing a loss of height. Over the next several months he experienced sudden, intense lower back pain and was diagnosed with a femur neck fracture. He had surgery with internal fixation, and stayed mainly in bed for the next 6 months. During this time, he recognised a growing tumour (around 2 cm) in the inner thigh of his right leg. This tumour progressively grew until it was around 4 x 10 cm. During this time he also lost height (going from 1.75 m to 1.65 m) and weight (losing 15–20 kg in total), and noticed kyphosis in the thoracic spine and sternum protrusion. While he was walking, he fell and suffered a pathologic right femoral fracture. On physical examination, his vital signs at presentation were normal and he was noted to have kyphosis, sternum protrusion, and no Harrison’s sulcus or pain at rib palpation (see Figure 1). Interestingly, a 4 x 10 cm tumour was noticed in the inner thigh of his right leg (rigid consistency, with rough edges, partially mobile and not painful). The neurologic evaluation and strength were unremarkable.

A biochemical evaluation (Table 1) was noteworthy for severe hypophosphatemia associated with hyperphosphaturia and reduced tubular reabsorption of phosphorus (0.5 g in 24-hour collection), low serum 1, 25(OH)2 D, increased serum alkaline phosphatase (ALP). The serum 25(OH) D levels were low and the FGF-23 was 389 RU/m. The remainder of the chemistry profile was within normal limits, including the serum calcium and intact parathyroid hormone (PTH). A diagnosis of hypophosphatemic osteomalacia due to a tumour was made. The magnetic resonance scanning demonstrated a 9 cm mass in the medial right femur, which involved bone and soft tissue (see Figure 2).

Resection of the lesion revealed a spindle cell sarcoma with areas of necrosis and nuclear atypia that showed tendency to collagenation, and although it did not form malignant osteoid, cells were positive in immunohistochemistry for osteonectin, which suggests osteoblastic and osteogenic origin with high-grade fibroblastic osteosarcoma being the best fit option, and whose association with hyperphosphaturia is very rare. The neoplasm was in touch with resection borders.

After surgery the patient persisted with low levels of phosphorus, and adjuvant chemotherapy was started with six cycles of adriamycin and cisplatin, with a consequent normalisation of phosphorus levels (2.7 mg/dl).

The first patient with TIO was reported in 1947 by McCance3 who attributed cure to high-dose vitamin D treatment. In 1964, in a similar case, Dent and Friedman4 described spontaneous recovery after surgical enucleation of the tumour and recognised the link between the neoplasm and metabolic bone disease. In 1959, Prader et al.5 were the first to recognise tumour (a giant cell reparative granuloma of the rib) as a cause of osteomalacia. Most of these cases were benign TIO and belong to the same histopathologic entity of phosphaturic mesenchymal tumour (PMC). In fact, Folpe,6 in a comprehensive review of the literature found that most of the cases reported as other pathologies were secondary to these. There have been, however, reported cases of

malignant tumours such as adenocarcinoma of the colon,7 prostate cancer, metastatic tumours, as well as oseteosarcoma.8–12

It is important to differentiate our case of malignant presentation PMC13– 15 since histologically fusiform cells present invasion, which differentiate them from mesenchymal tumours. In this case, unlike the previous reported osteosarcoma, we had levels of FGF-23 that decreased after surgery, however, they will not be normalised until after treatment with chemotherapy. Because of the high recurrence risk in these tumours, it is important to keep monitoring this patient (that is, initially with serum and urine phosphorus).

FGF-23 inhibits the NaPO4 renal co-transporter and also suppresses 1α-hydroxylase activity, resulting in decreased renal reabsorption and increased urine excretion of the phosphate. When a tumour is surgically unresectable or not localised after an extensive workup, oral combined with phosphate treatment, calcium, and calcitriol is recommended, along with phosphate monitoring, a treatment similar to that used in the genetics forms (autosomal dominant hypophosphatemic rickets [ADHR], X-linked). In our case, the tumour was relatively easy to find. Most tumours are found in the extremities, but conventional X-ray, magnetic resonance imaging (MRI), and computed tomography (CT) scans are usually not sufficient for tumour identification and localisation. Because these tumours typically express somatostatin receptors, functional imaging with radiolabeled somatostatin analogs (for example, 111-Indium octreotide scintigraphy or [68Ga] DOTATATEPET [preferably in combination with CT]) is probably the most valuable diagnostic tool. The treatment of TIO is resection of the tumour and the symptoms and phosphorus levels return to normal. If the tumour is not found, usually we must continue with medical treatment with phosphorus supplementation and vitamin D. Overall, the tumour prognosis is good, however, in our patient, due to the diagnosis of sarcoma, close follow-up will be mandatory.

TIO, which is currently not frequently suspected, generally occurs when the disease is advanced and the patient has experienced multiple fractures and other complications. Usually they are benign tumours however, as in our case, a small proportion of them can be malignant.

Article Information:

Karla Victoria Rodriguez-Velver, María Azucena Zapata-Rivera, Juan Montes-Villarreal, Fernando Javier Lavalle-González, José Gerardo González-González, Jesús Zacarías Villarreal-Pérez, and Rene Rodríguez- Gutierrez have nothing to declare in relation to this article. No funding was received for the publication of this article.
Compliance with Ethics: All procedures were followed in accordance with the responsible committee on human experimentation and with the Helsinki Declaration of 1975 and subsequent revisions, and informed consent was received from the patient involved in this case study.


Rene Rodríguez-Gutiérrez, Servicio de Endocrinología. Hospital Universitario ‘Dr José E González’, Universidad Autónoma de Nuevo León, Madero y Gonzalitos S/N, Monterrey Nuevo León, 64460, México. E:


This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.




1. Chong WH, Molinolo A, Chen CC, Collins MT, Tumor-induced osteomalacia, Endocr Relat Cancer, 2011;18:R53–77.
2. Shimada T, Mizutani S, Muto T, et al., Cloning and characterization of FGF23 as a causative factor of tumorinduced osteomalacia, Proc Natl Acad Sci U S A, 2001;98, 6500–5.
3. McCance R, Osteomalacia with Looser’s nodes (Milkman’s syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years, Q J Med, 1947;16:33–46.
4. Dent CE, Friedman M, Hypophosphataemic Osteomalacia With Complete Recovery, Br Med J, 1964;1:1676–9.
5. Prader A, Illig R, Uehlinger E, Rickets following bone tumor, Helv Paediatr Acta, 1959;14:554–65.
6. Folpe AL, Fanburg-Smith JC, Billings SD, et al., Most osteomalaciaassociated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature, Am J Surg Pathol, 2004;28:1–30.
7. Leaf DE, Pereira RC, Bazari H, Jüppner H, Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma, J Clin Endocrinol Metab, 2013;98:887–91.
8. Wyman AL, Paradinas FJ, Daly JR, Hypophosphataemic osteomalacia associated with a malignant tumour of the tibia: report of a case,J Clin Pathol, 1977;30:328–35.
9. Cheng CL, Ma J, Wu PC, et al., Osteomalacia secondary to osteosarcoma. A case report, J Bone Joint Surg Am, 1989;71:288–92.
10. Lamont EB, Cavaghan MK, Brockdtein BE, Oncogenic osteomalacia as a harbinger of recurrent osteosarcoma, Sarcoma, 1999;3:95–9.
11. Hasegawa T, Shimoda T, Yokoyama R, et al., Intracortical osteoblastic osteosarcoma with oncogenic rickets, Skeletal Radiol, 1999;28:41–5.
12. Nomura G, Koshino Y, Morimoto H, et al., Vitamin D resistant hypophosphatemic osteomalacia associated with osteosarcoma of the mandible: report of a case, Japan J Med, 1982;21:35–9.
13. Chiam P, Tan HC, Bee YM, Chandran M, Oncogenic osteomalacia - hypophosphataemic spectrum from ‘benignancy’ to ‘malignancy’, Bone, 2013;53:182–7.
14. Ogose A, Hotta T, Emura I, et al., Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia, Skeletal Radiol, 2001;30:99–103.
15. Higley M, Beckett B, Schmahmann S, et al., Locally aggressive and multifocal phosphaturic mesenchymal tumors: two unusual cases of tumor-induced osteomalacia, Skeletal Radiol, 2015;44:1825–31.

Further Resources

Share this Article
Related Content In Endocrine Oncology
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72